Gemtuzumab/gemtuzumab (MYLOTARG), a specific drug for acute myeloid leukemia

Gemtuzumab/Gemtuzumab (MYLOTARG) is a specific drug used to treat acute myeloid leukemia (AML). AMLIt is a malignant disease caused by the abnormal proliferation of immature myeloid cells in the bone marrow. It usually manifests as a rapid increase in abnormal white blood cells in the blood, causing the body to be unable to produce healthy blood cells normally.

Gemtuzumab/The specific efficacy of gemtuzumab in the treatment ofAML is attributed to its unique targeted therapeutic mechanism. Here are some key information about Gemtuzumab/Gemtuzumab:

1. Targeting effect:Gemtuzumab/Gemtuzumab is a monoclonal antibody drug that specifically binds to the CD33 antigen on the surface of AML cells. CD33 is a protein highly expressed on the surface of AML cells, while normal bone marrow cells usually express less or no CD33. Gemtuzumab/Gemtuzumab uses this specific binding effect to guide the drug directly to AML cells, thereby reducing damage to normal cells.

2. Immune system activation: Oncegemtuzumab/gemtuzumab binds to the CD33 antigen, it can activate the host immune system, such as natural killer cells (NK cells) and macrophages. These immune cells will be activated, coaxing them to attack and destroy CD33-positive AML cells. This involvement of the immune system enhances the effectiveness of the treatment because it uses the body's own defense mechanisms to fight cancer cells.

3. Indications:Gemtuzumab/Gemtuzumab is usually used to treat AML patients, especially in treatment-naïve AML patients span>CD33positiveAML, as well as relapsedAMLpatients or AMLpatients who cannot tolerate traditional treatment.

4. Individualized treatment:Gemtuzumab/The dosage and treatment plan of gemtuzumab should be individually adjusted based on the patient’s specific condition and the doctor’s recommendations. This means there is no one fixed dose that works for all patients, so your doctor's advice is crucial.

5. Related side effects: The use of Gemtuzumab/Gemtuzumab may cause some side effects, including fever, headache, nausea, vomiting, anemia, thrombocytopenia, leukopenia, abnormal liver function, etc. Patients need to be aware of these potential adverse reactions and promptly report any unusual symptoms to their doctor.

In short,Gemtuzumab/Gemtuzumab, as a specific drug for acute myeloid leukemia, is expected to improve the success rate of treatment for AML patients through its unique targeted therapy mechanism. However, patients need to be under the supervision of a doctor during treatment and pay close attention to the treatment plan, dosage, and side effects. The doctor will develop a personalized treatment plan based on the patient's condition to ensure the best treatment effect and patient safety.

Gemtuzumab/GemtuzumabIt is not currently on the market in China, so it cannot be included in medical insurance. Patients cannot purchase it domestically and need to purchase it through overseas channelsGemtuzumab/Gemtuzumab. Foreign Gemtuzumab/Gemtuzumab is only Pfizer’s original drug, which is expensive, and the cheaper ones are mainly Turkish original drugs. The price of the drug is around 45,000 yuan, and the price of the original drug in Hong Kong, China is around 65,000 yuan, and the ingredients and efficacy of the original drug are consistent.